文献速递治疗药物监测与药物基因组学特殊人群用药

肾移植受者伏立康唑群体药代动力学与CYP2C19多态性优化给药方案

Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
PubMed 文献 · Br J Clin Pharmacol · 2018-05-06

该前瞻性群体药代动力学研究纳入105例肾移植受者(342个浓度点),用非线性混合效应模型分析伏立康唑药代动力学,发现CYP2C19基因型显著影响清除率,术后时间影响口服生物利用度,据此模拟并推荐按CYP2C19基因型与术后时间确定初始剂量,并结合治疗药物监测实现个体化治疗。

要点

  • CYP2C19基因型显著影响伏立康唑清除率,慢代谢者谷浓度显著高于中间和快代谢者。
  • 口服生物利用度在移植后1个月内明显降低,并随术后时间延长而升高。
  • 早期术后可按CYP2C19基因型选择初始剂量,后续结合治疗药物监测调整。

核心结论

  • 联合CYP2C19基因型与术后时间确定伏立康唑初始剂量并后续开展治疗药物监测,有助于推进肾移植合并侵袭性真菌感染患者的个体化治疗。

研究设计与样本

  • 前瞻性群体药代动力学分析纳入105例肾移植受者,共342个伏立康唑浓度点,使用Phoenix NLME软件构建非线性混合效应模型并进行给药模拟。

主要发现

  • 伏立康唑药代动力学采用一级吸收和消除的一室模型描述,群体清除率估计为2.88 l·h-1,表观分布容积为169.3 l,口服生物利用度为58%。
  • CYP2C19*2、*3和*17等位基因频率分别为29.2%、5.2%和0.5%,CYP2C19基因型对清除率有显著影响。
  • 慢代谢者伏立康唑谷浓度显著高于中间代谢者和快代谢者。
  • 表观分布容积随体重增加而增大,口服生物利用度在移植后1个月内明显较低但随术后时间延长而升高。

关键数值与推荐

  • 术后早期模拟给药方案:慢代谢者可静脉150 mg或口服250 mg每日两次;中间代谢者可静脉200 mg或口服350 mg每日两次;快代谢者可静脉300 mg每日两次。

临床怎么用

  • 临床可依据CYP2C19基因型和术后时间确定伏立康唑初始剂量,并开展治疗药物监测以指导后续剂量调整。
  • 对慢代谢者需关注伏立康唑谷浓度偏高风险,对移植后早期患者需考虑口服生物利用度降低的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims of the present study were to characterize the pharmacokinetics of voriconazole in renal transplant recipients and to identify factors significantly affecting pharmacokinetic parameters. We also aimed to explore the optimal dosing regimens for patients who developed invasive fungal infections. METHODS: A total of 105 patients (342 concentrations) were included prospectively in a population pharmacokinetic analysis. Nonlinear mixed-effects models were developed using Phoenix NLME software. Dosing simulations were performed based on the final model. RESULTS: A one-compartment model with first-order absorption and elimination was used to characterize voriconazole pharmacokinetics. Population estimates of clearance, volume of distribution and oral bioavailability were 2.88 l·h-1 , 169.3 l and 58%, respectively. The allele frequencies of cytochrome P450 gene (CYP) 2C19*2, *3 and *17 variants were 29.2%, 5.2% and 0.5%, respectively. CYP2C19 genotype had a significant effect on the clearance. Voriconazole trough concentrations in poor metabolizers were significantly higher than in intermediate metabolizers and extensive metabolizers alike. The volume of distribution increased with increased body weight. The oral bioavailability was substantially lower within 1 month after transplantation but increased with postoperative time. Dosing simulations indicated that during the early postoperative period, poor metabolizers could be treated with 150 mg intravenously or 250 mg orally twice daily; intermediate metabolizers with 200 mg intravenously or 350 mg orally twice daily; and extensive metabolizers with 300 mg intravenously twice daily. CONCLUSIONS: Using a combination of CYP2C19 genotype and postoperative time to determine the initial voriconazole dosing regimens followed by therapeutic drug monitoring could help to advance individualized treatment in renal transplantation patients with invasive fungal infections.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lin XB, Li ZW, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 2018. PMID: 29607533. doi:10.1111/bcp.13595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。